STOCK TITAN

Climb Bio to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Climb Bio (Nasdaq: CLYM) has announced its executive team's participation in four major upcoming healthcare investor conferences. The schedule includes appearances at the Guggenheim Securities Healthcare Innovation Conference (Nov 11-12), Stifel Healthcare Conference (Nov 18-19), Piper Sandler Healthcare Conference (Dec 3-5), and Evercore ISI HealthCONx Conference (Dec 3-5). Each event will feature fireside chats and one-on-one investor meetings. All presentations will be webcast live and available for replay on the company's website under the Investors section.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • None.

Negative

  • None.

News Market Reaction – CLYM

-2.42%
1 alert
-2.42% News Effect

On the day this news was published, CLYM declined 2.42%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.

Guggenheim Securities Healthcare Innovation Conference
Format: Fireside chat and one-on-one investor meetings
Date: November 11-12, 2024

Stifel 2024 Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: November 18-19, 2024

36th Annual Piper Sandler Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: December 3-5, 2024

7th Annual Evercore ISI HealthCONx Conference
Format: Fireside chat and one-on-one investor meetings
Date: December 3-5, 2024

The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at climbbio.com.

About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

Investors
Chris Brinzey
ICR Healthcare
chris.brinzey@ICRhealthcare.com
339-970-2843

Media
Jon Yu
ICR Healthcare
jon.yu@icrhealthcare.com
475-395-5375


FAQ

What investor conferences will Climb Bio (CLYM) attend in late 2024?

Climb Bio will attend four conferences: Guggenheim Securities Healthcare Innovation Conference (Nov 11-12), Stifel Healthcare Conference (Nov 18-19), Piper Sandler Healthcare Conference (Dec 3-5), and Evercore ISI HealthCONx Conference (Dec 3-5).

Where can investors watch Climb Bio's (CLYM) conference presentations?

Investors can watch the live webcasts and replays of Climb Bio's presentations on the company's website (climbbio.com) under the 'News & Events' section of the Investors page.

What type of sessions will Climb Bio (CLYM) participate in at these conferences?

Climb Bio will participate in fireside chat sessions and one-on-one investor meetings at all four conferences.